http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2022054487-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71902e53dae946ec51814b9c4679b555
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
filingDate 2019-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca36e25b895212559b08c9b3ebc86383
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_114899353a8be43c03de045a3f0c9e08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b8bab74ac90f9c3e0577e3107d4672dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_326c040986d3a406891d75430946bd25
publicationDate 2022-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2022054487-A1
titleOfInvention Methods for treating heterotopic ossification
abstract The invention describes dosing regimens for treating subjects with fibrodysplasia ossificans progressiva characterized by a quiescent period and a non-quiescent period, wherein a therapeutically effective amount of palovarotene is administered to the subjects during the non-quiescent period, little or no palovarotene is administered to the subjects during the quiescent period, and imatinib is administered to the subjects during the quiescent period and optionally during the non-quiescent period. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
priorityDate 2018-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID19411
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID123596
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID228001325
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID685072
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6251
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454269980
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP28699
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410531777
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID18677595
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID5916
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30615
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP18911
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A286ZM53
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID89264747
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID16134267
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID453
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424505814
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID230565865
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10295295
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID540425
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF1PN60
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID421342529
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410916410
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393712
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395397
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399463
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534036
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID90
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID451935
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393714
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP18516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454406839
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID947861
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414871259
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444795
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID107428
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCF6VXM9
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12629
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID229455
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID11477
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCA0A5F4D9R6
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID12403617
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449943201
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2760897
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399639
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID486508
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID397983
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395931
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID30606

Total number of triples: 73.